PUBLISHED DATE : Jul 2022 | Pages : 317
Fill out your details & get your free sample
Global Biopharmaceuticals Excipients Market Research Report Includes Size in Terms of
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2022–2027
317 Pages
112 Tables
175 Charts
5 Regions
20 Countries
33 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2027) | USD 3.23 Billion |
| Market Size (2021) | USD 2.08 Billion |
| CAGR (2022-2027) | 7.56% |
| Base Year | 2021 |
| Forecast Year | 2022-2027 |
| Market Segments | Excipient, Biologics, Scale of Operation |
| Geographic Analysis | North America, APAC, Europe, Latin America, and MEA |
| KEY VENDORS | Merck KGAA, BASF SE, Avantor, Evonik Industries, and Roquette |
The global biopharmaceutical excipients market was valued at $2.08 billion in 2021 and is expected to reach $3.2 billion by 2027, growing at a CAGR of 7.56% from 2022 to 2027. Excipients are fundamental components of any biopharmaceutical drug product, which act as active ingredients, stability enhancers, emulsifying and suspending agents, binders, preservatives, antioxidants, and lubricants. These differ from prodrugs in manufacturing or are present in a finished pharmaceutical product dosage form. Excipients have targeted roles, ranging from protecting the API to easing the manufacturing process, which, in turn, drives the need and stipulation of excipients for developing effective formulations.
The constant shift of trends in the pharma sector, including new drug development, continuous manufacturing, and innovative drug technologies, has donated to a surge in demand for excipients with advanced functions. Between 40-70% of marketed drugs and up to 90% of all new chemical entities (NCEs) registered to suffer from poor water solubility. This can have significant negative consequences on the bioavailability of the active pharmaceutical ingredient (API), potentially impacting the therapeutic effect. The market for solubility-enhancing excipients and related technologies is proliferating to tackle the problem.
High-concentration biologic formulations account for an increasing percentage of the drug development pipeline as drug manufacturers seek to offer advanced therapeutics that the patient or caregiver can administer in the home setting. These high concentrations include protein-protein interactions due to higher viscosities. Excipients can help minimize these interactions without negatively impacting protein stability and other aspects of biologic formulations. This is driving a shift towards carefully selected combinations of viscosity-reducing excipients.
Biologics- Pipeline and Product Approvals, a Major driver for Biopharmaceutical Excipients Market
With a growing number of infectious diseases and cancers, there is a high demand for various biologic drugs. Innovative biopharmaceutical companies are continuously operating with stakeholders across the R&D landscape for the expansion of newer ways to treat such diseases. To date, 258 vaccines are in the pipeline for treating and preventing severe infectious diseases. According to a study, trends in global vaccine R&D found that the proportion of new vaccine candidates entering all stages of clinical development increased by 3–5 percentage points over the past two decades. Small and medium-sized companies accounted for nearly twice as many new Phase I vaccine trials as large companies, but large companies dominated late-stage (Phase III) vaccine trials.
The biologics industry is increasing, with an estimated 40% of biopharmaceuticals in the industry pipeline. Biological products are the fastest-growing class of therapeutic products, especially in the U.S. Since 2000, more than 475 new prescription medicines (new molecular entities (NMEs) and new biologics license applications) have been approved for use by the U.S. Food and Drug Administration. The growing approvals of biopharmaceuticals will likely increase the need for novel excipients used in their formulation and contribute to market growth.
Novel Excipients Creating a Major Shift from Traditional Excipients
As drug substances become increasingly complex, formulation challenges will continue to grow. Novel excipients can significantly impact drug development and, by extension, the number and types of treatments available to patients. A novel excipient differs from an excipient in that it has not been previously used in an approved drug. In an essential step for modernizing drug formulation and biopharmaceutical development, FDA is launching a program to test the safety and suitability of novel inactive ingredients for use in new drugs and biologics. The aim is to encourage sponsors of clinical trials to formulate innovative therapies with those new excipients that FDA finds acceptable for use under this program.
Growing Trend Outsourcing the Manufacture of Biopharmaceutical Excipients
In today's market, pharmaceutical companies cite improved quality and faster time to market as the main reasons for outsourcing business functions to contract research organizations (CROs) and contract development and research organizations (CDMOs). Formulators are increasingly facing complexity with ingredients in their drug products and incorporating multiple active elements, increasing regulations, changing social and consumer preferences, and environmental implications impact production and eventual decomposition. This led to the outsourcing of ingredients manufacturing which also includes excipients as a significant component.
Challenges Restraining the Growth of Biopharmaceutical Excipients
The quality and safety of pharmaceutical products are the top concerns of regulators. In recent years, regulatory agencies have strengthened their position on preventing drug adulteration in active pharmaceutical ingredients (API) and excipients by enacting new regulations. However, the current regulatory landscape or lack of an independent excipient approval pathway can limit the entrance of new excipients into the market and, subsequently, new drug products.
Many challenges are associated with excipient quality management, managing extended supply chains, and developing certification schemes for producing and supplying excipients. Not satisfactorily meeting these challenges creates the potential for counterfeit or substandard excipients to enter the supply chain. Furthermore, several challenges also exist in formulating biological drug products using excipients due to the complexity and fragility of the active compounds.
Impact of COVID-19 on Biopharmaceutical Excipients
During the pandemic, companies rushed to develop new biopharmaceuticals, drug products, vaccines, and re-purpose older drug products. Due to this, the importance of the critical function excipients in these products has risen. Excipients played a vital role in the progression of new biopharmaceuticals, pharmaceuticals, and vaccines to fight COVID-19 and other diseases. Therefore, various excipients are required to stabilize biologics and vaccines during processing and storage. Selection and use of the appropriate excipients enabled the development of novel therapies and robust pharmaceutical products.
By Excipient
The global biopharmaceutical excipients market is segmented by bulking agents, solubilizers & surfactants, buffering & tonicity agents, and others. In 2021, bulking agents accounted for the highest share of 39% and were expected to have the most significant incremental growth during the forecast period.
By Biologics
Biologics included monoclonal antibodies, vaccines, recombinant proteins, cell and gene therapy, interferons, growth factors, and others. In 2021, monoclonal antibodies accounted for the highest share of 45.04% and were expected to have the most significant incremental growth during the forecast period. A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to an individual parent cell. Monoclonal antibodies can have monovalent affinity, binding only to the same epitope (the part of an antigen recognized by the antibody). In contrast, polyclonal antibodies bind to multiple epitopes and are usually made by several different antibody-secreting plasma cell lineages. Bispecific monoclonal antibodies can also be engineered by increasing the therapeutic targets of one monoclonal antibody to two epitopes.
Vaccines are inherently less stable than small molecules, and formulation development is often challenging with stringent product development timelines. Their complex molecular structure, lack of well-defined stability-indicating assays, and a multitude of degradation mechanisms create significant hurdles for the formulation development of vaccines.
By Scale of Operation
The global biopharmaceutical excipients market is segmented by commercial and research. In 2021, retail accounted for the highest share of 73.20% and was expected to grow with the highest incremental and absolute growth of $862.44 million and 56.60%, respectively, during the forecast period.
With growing infectious diseases and the onset of epidemics and pandemics, there is a massive demand for manufacturing a billion doses of biologics within months. With a greater uptake of biologics, the need for manufacturing high quantities of these drugs is increasing. Biopharmaceutical manufacturing large-scale drug substances and products is a highly challenging task. With a high patient population in the commercial phase, the rapid development of large-scale production is a critical step that requires enormous volumes of ingredients.
By End-user
The global biopharmaceutical excipients market is segmented by pharma & biotech companies, CMOs & CDMOs, and academic & research institutes. In 2021, pharma & biotech companies accounted for the highest share of 57.63% and were expected to have the most significant incremental growth of $640.83 million during the forecast period.
With growing infectious diseases and the onset of epidemics and pandemics, there is a massive demand for manufacturing a billion doses of biologics within months. With a greater uptake of biologics, the need for manufacturing high quantities of these drugs is increasing. Biopharmaceutical manufacturing large-scale drug substances and products is a highly challenging task. With a high patient population in the commercial phase, the rapid development of large-scale production is a critical step that requires enormous volumes of ingredients.
By Geography
In 2021, North America dominated the global biopharmaceutical excipients market with 34.10%. However, APAC is likely the fastest-growing region in the worldwide biopharmaceutical excipients market, with the highest CAGR of 9.01% during the forecast period. The North American biopharmaceuticals market is well established, with prominent biopharmaceutical manufacturing companies based in the region. The rise in drug development has significantly increased the demand for biopharmaceutical excipients in this region. The US is the major revenue contributor in North America mainly due to an increase in the vaccine market, reflecting the growth in awareness of vaccinations and their benefits against infectious diseases.
Increasing populations, the emergence of infections, demand for vaccines, improved biopharma facilities, and the advent of COVID-19 are significant factors boosting the demand for biopharmaceutical excipients in Europe. However, APAC is the fastest-growing region for biopharmaceutical excipients. Emerging countries such as China and Japan are the major players due to low labor costs and increased outsourcing of inorganic and organic chemicals manufacturing. Latin America, the Middle East, & Africa accounted for minor shares in the global biopharmaceutical excipients market.
The global biopharmaceutical excipients market is fragmented, with vendors ranging from emerging mid-sized to established players contributing to its revenue. Most of the leading players focus on implementing various strategies such as product launches and approvals, marketing, and promotional activities, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market. For instance, in 2020, DFE Pharma launched a new portfolio of biopharmaceutical excipients for stabilizing biologics to capitalize on increasing growth in the biologics sector. In the same year, MilliporeSigma agreed with ReForm Biologics to commercialize ReForm's excipients used in biotherapeutic formulations.
Established players that accounted for a significant share in the global biopharmaceutical excipients market include Merck KGaA, DFE Pharma, Avantor, BASF SE, Evonik Industries AG, and Rouquette Freres. Other prominent vendors that are emerging in the global biopharmaceutical excipients market are Aceto, Ashland Global Holdings, Biohale, Biospectra, Clariant, Colorcon, Dow Chemical Industries, Fuji Chemical Industries, IMCD, Innophos, JRS Pharma, Kirsch Pharma, Novo Nordisk, Pfanstiehl, Pharmonix Biologicals, Sigachi Industries.
Frequently Asked Questions
How big is the biopharmaceutical excipients market?
The global biopharmaceutical excipients market was valued at $2.08 billion in 2021 and is expected to reach $3.2 billion by 2027.
What is the biopharmaceutical excipients market growth?
The global biopharmaceutical excipients market is expected to grow at a CAGR of 7.56%.
Who are the market leaders in the global biopharmaceutical industry?
Merck KGAA, BASF SE, Avantor, Evonik Industries, and Roquette Freres are the market leaders.
What are the top trends driving the market growth?
The growing prevalence of Cancer and Infectious Diseases, the Rising Number of Product Approvals for biologics, and the Increasing Need For Outsourcing Biopharmaceuticals Excipients are the market growth trends.
The global biopharmaceutical excipients market was valued at $2.08 billion in 2021 and is expected to reach $3.2 billion by 2027, growing at a CAGR of 7.56% from 2022 to 2027.
The following factors are likely to contribute to the growth of the global biopharmaceuticals excipients market during the forecast period:
Base Year: 2021
Forecast Year: 2022–2027
The study considers the present scenario of the global biopharmaceutical excipients market and its market dynamics for 2022−2027. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Vendors
Other Prominent Vendors
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY EXCIPIENT
4.3.2 MARKET SEGMENTATION BY BIOLOGICS
4.3.3 MARKET SEGMENTATION BY SCALE OF OPERATION
4.3.4 MARKET SEGMENTATION BY END-USER
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
7.2 MARKET SYNOPSIS
7.2.1 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET SCENARIO
7.2.2 BIOLOGICS – PIPELINE AND PRODUCT APPROVALS, A MAJOR DRIVER FOR BIOPHARMACEUTICAL EXCIPIENTS
7.2.3 NOVEL EXCIPIENTS CREATING A MAJOR SHIFT FROM TRADITIONAL EXCIPIENTS
7.2.4 GROWING TREND OF OUTSOURCING THE MANUFACTURE OF BIOPHARMACEUTICAL EXCIPIENTS
7.2.5 CHALLENGES RESTRAINING THE GROWTH OF BIOPHARMACEUTICAL EXCIPIENTS
7.2.6 IMPACT OF COVID-19 ON BIOPHARMACEUTICAL EXCIPIENTS
7.2.7 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS: MARKET SEGMENTATIONS
7.2.8 COMPETITIVE LANDSCAPE
8 MARKET OPPORTUNITIES & TRENDS
8.1 EMERGING DEMAND FOR NOVEL EXCIPIENTS IN DRUG PRODUCT DEVELOPMENT
8.2 HIGH DEMAND FOR VACCINES AND CELL & GENE THERAPY-BASED EXCIPIENTS
8.3 EXHAUSTIVE PIPELINE OF BIOLOGICS & BIOSIMILARS
8.4 GROWING PENETRATION OF BIOPHARMACEUTICAL DRUGS
9 MARKET GROWTH ENABLERS
9.1 GROWING PREVALENCE OF CANCER AND INFECTIOUS DISEASES
9.2 RISING NUMBER OF PRODUCT APPROVALS FOR BIOLOGICS
9.3 INCREASING NEED FOR OUTSOURCING BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING
9.4 EMERGING NEED FOR MULTI-FUNCTIONAL EXCIPIENTS
10 MARKET RESTRAINTS
10.1 REGULATORY CHALLENGES IN MANUFACTURING BIOPHARMACEUTICAL EXCIPIENTS
10.2 SUPPLY CHAIN AND INTEGRITY ISSUES WITH BIOPHARMACEUTICAL EXCIPIENTS
10.3 CHALLENGES OF FORMULATING BIOPHARMACEUTICAL EXCIPIENTS
11 MARKET LANDSCAPE
11.1 MARKET OVERVIEW
11.2 MARKET SIZE & FORECAST
11.2.1 INSIGHTS BY EXCIPIENT
11.2.2 INSIGHTS BY BIOLOGICS
11.2.3 INSIGHTS BY SCALE OF OPERATION
11.2.4 INSIGHTS BY END-USERS
11.2.5 INSIGHTS BY GEOGRAPHY
11.2.6 IMPACT OF COVID-19
11.3 FIVE FORCES ANALYSIS
11.3.1 THREAT OF NEW ENTRANTS
11.3.2 BARGAINING POWER OF SUPPLIERS
11.3.3 BARGAINING POWER OF BUYERS
11.3.4 THREAT OF SUBSTITUTES
11.3.5 COMPETITIVE RIVALRY
12 EXCIPIENT
12.1 MARKET SNAPSHOT & GROWTH ENGINE
12.2 MARKET OVERVIEW
12.3 BULKING AGENTS
12.3.1 MARKET OVERVIEW
12.3.2 MARKET SIZE & FORECAST
12.3.3 BULKING AGENTS: GEOGRAPHY SEGMENTATION
12.4 SOLUBILIZERS & SURFACTANTS
12.4.1 MARKET OVERVIEW
12.4.2 MARKET SIZE & FORECAST
12.4.3 SOLUBILIZERS & SURFACTANTS: GEOGRAPHY SEGMENTATION
12.5 BUFFERING & TONICITY AGENTS
12.5.1 MARKET OVERVIEW
12.5.2 MARKET SIZE & FORECAST
12.5.3 BUFFERING & TONICITY AGENTS: GEOGRAPHY SEGMENTATION
12.6 OTHERS
12.6.1 MARKET OVERVIEW
12.6.2 MARKET SIZE & FORECAST
12.6.3 OTHERS: GEOGRAPHY SEGMENTATION
13 BIOLOGICS
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 MONOCLONAL ANTIBODIES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MONOCLONAL ANTIBODIES: GEOGRAPHY SEGMENTATION
13.4 VACCINES
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 VACCINES: GEOGRAPHY SEGMENTATION
13.5 OTHERS
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 OTHERS: GEOGRAPHY SEGMENTATION
14 SCALE OF OPERATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 COMMERCIAL
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 COMMERCIAL: GEOGRAPHY SEGMENTATION
14.4 RESEARCH
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 RESEARCH: GEOGRAPHY SEGMENTATION
15 END-USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 PHARMA & BIOTECH COMPANIES
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
15.4 CMOS & CDMOS
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 CMOS & CDMOS: GEOGRAPHY SEGMENTATION
15.5 ACADEMIC & RESEARCH INSTITUTES
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 ACADEMIC & RESEARCH INSTITUTES: GEOGRAPHY SEGMENTATION
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.2.1 NORTH AMERICA: EXCIPIENT
17.2.2 NORTH AMERICA: BIOLOGICS
17.2.3 NORTH AMERICA: SCALE OF OPERATION
17.2.4 NORTH AMERICA: END-USER
17.3 KEY COUNTRIES
17.3.1 US: MARKET SIZE & FORECAST
17.3.2 CANADA: MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.2.1 EUROPE: EXCIPIENT
18.2.2 EUROPE: BIOLOGICS
18.2.3 EUROPE: SCALE OF OPERATION
18.2.4 EUROPE: END-USER
18.3 KEY COUNTRIES
18.3.1 GERMANY: MARKET SIZE & FORECAST
18.3.2 FRANCE: MARKET SIZE & FORECAST
18.3.3 UK: MARKET SIZE & FORECAST
18.3.4 SWITZERLAND: MARKET SIZE & FORECAST
18.3.5 ITALY: MARKET SIZE & FORECAST
18.3.6 SPAIN: MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.2.1 APAC: EXCIPIENT
19.2.2 APAC: BIOLOGICS
19.2.3 APAC: SCALE OF OPERATION
19.2.4 APAC: END-USER
19.3 KEY COUNTRIES
19.3.1 CHINA: MARKET SIZE & FORECAST
19.3.2 JAPAN: MARKET SIZE & FORECAST
19.3.3 SOUTH KOREA: MARKET SIZE & FORECAST
19.3.4 INDIA: MARKET SIZE & FORECAST
19.3.5 AUSTRALIA: MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.2.1 LATIN AMERICA: EXCIPIENT
20.2.2 LATIN AMERICA: BIOLOGICS
20.2.3 LATIN AMERICA: SCALE OF OPERATION
20.2.4 LATIN AMERICA: END-USER
20.3 KEY COUNTRIES
20.3.1 BRAZIL: MARKET SIZE & FORECAST
20.3.2 MEXICO: MARKET SIZE & FORECAST
20.3.3 ARGENTINA: MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.2.1 MIDDLE EAST & AFRICA: EXCIPIENT
21.2.2 MIDDLE EAST & AFRICA: BIOLOGICS
21.2.3 MIDDLE EAST & AFRICA: SCALE OF OPERATION
21.2.4 MIDDLE EAST & AFRICA: END-USER
21.3 KEY COUNTRIES
21.3.1 TURKEY: MARKET SIZE & FORECAST
21.3.2 SAUDI ARABIA: MARKET SIZE & FORECAST
21.3.3 UAE: MARKET SIZE & FORECAST
21.3.4 SOUTH AFRICA: MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
22.2.1 MERCK KGAA
22.2.2 BASF SE
22.2.3 AVANTOR
22.2.4 EVONIK INDUSTRIES
22.2.5 ROQUETTE FRÈRES
22.2.6 ASSOCIATED BRITISH FOODS
23 KEY COMPANY PROFILES
23.1 MERCK KGAA
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 BASF SE
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 AVANTOR
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 EVONIK INDUSTRIES
23.4.1 BUSINESS OVERVIEW
23.4.2 PRODUCT OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 ROQUETTE FRÈRES
23.5.1 BUSINESS OVERVIEW
23.5.2 PRODUCT OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 ASSOCIATED BRITISH FOODS
23.6.1 BUSINESS OVERVIEW
23.6.2 PRODUCT OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.6.5 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 ACETO
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.2 ANGUS CHEMICAL COMPANY
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.3 APOTHECON PHARMACEUTICALS
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.4 ASHLAND
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.5 BIOSPECTRA
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.6 BOC SCIENCES
24.6.1 BUSINESS OVERVIEW
24.6.2 PRODUCT OFFERINGS
24.7 CG GROUP
24.7.1 BUSINESS OVERVIEW
24.7.2 PRODUCT OFFERINGS
24.8 CLARIANT
24.8.1 BUSINESS OVERVIEW
24.8.2 PRODUCT OFFERINGS
24.9 COLORCON
24.9.1 BUSINESS OVERVIEW
24.9.2 PRODUCT OFFERINGS
24.10 DFE PHARMA
24.10.1 BUSINESS OVERVIEW
24.10.2 PRODUCT OFFERINGS
24.11 DOW
24.11.1 BUSINESS OVERVIEW
24.11.2 PRODUCT OFFERINGS
24.12 EASTMAN CHEMICAL COMPANY
24.12.1 BUSINESS OVERVIEW
24.12.2 PRODUCT OFFERINGS
24.13 IMCD
24.13.1 BUSINESS OVERVIEW
24.13.2 PRODUCT OFFERINGS
24.14 INNOPHOS
24.14.1 BUSINESS OVERVIEW
24.14.2 PRODUCT OFFERINGS
24.15 INVITRIA
24.15.1 BUSINESS OVERVIEW
24.15.2 PRODUCT OFFERINGS
24.16 JRS PHARMA
24.16.1 BUSINESS OVERVIEW
24.16.2 PRODUCT OFFERINGS
24.17 KIRSCH PHARMA
24.17.1 BUSINESS OVERVIEW
24.17.2 PRODUCT OFFERINGS
24.18 MEGGLE
24.18.1 BUSINESS OVERVIEW
24.18.2 PRODUCT OFFERINGS
24.19 NOVO NORDISK
24.19.1 BUSINESS OVERVIEW
24.19.2 PRODUCT OFFERINGS
24.20 PFANSTIEHL
24.20.1 BUSINESS OVERVIEW
24.20.2 PRODUCT OFFERINGS
24.21 PHARMONIX BIOLOGICALS
24.21.1 BUSINESS OVERVIEW
24.21.2 PRODUCT OFFERINGS
24.22 SHIN-ETSU CHEMICAL
24.22.1 BUSINESS OVERVIEW
24.22.2 PRODUCT OFFERINGS
24.23 SIGACHI INDUSTRIES
24.23.1 BUSINESS OVERVIEW
24.23.2 PRODUCT OFFERINGS
24.24 SPECTRUM CHEMICAL
24.24.1 BUSINESS OVERVIEW
24.24.2 PRODUCT OFFERINGS
24.25 TEREOS
24.25.1 BUSINESS OVERVIEW
24.25.2 PRODUCT OFFERINGS
24.26 THE LUBRIZOL CORPORATION
24.26.1 BUSINESS OVERVIEW
24.26.2 PRODUCT OFFERINGS
24.27 WACKER CHEMIE
24.27.1 BUSINESS OVERVIEW
24.27.2 PRODUCT OFFERINGS
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 EXCIPIENT
26.1.1 NORTH AMERICA: EXCIPIENT SEGMENTATION
26.1.2 EUROPE: EXCIPIENT SEGMENTATION
26.1.3 APAC: EXCIPIENT SEGMENTATION
26.1.4 LATIN AMERICA: EXCIPIENT SEGMENTATION
26.1.5 MIDDLE EAST & AFRICA: EXCIPIENT SEGMENTATION
26.2 BIOLOGICS
26.2.1 NORTH AMERICA: BIOLOGICS SEGMENTATION
26.2.2 EUROPE: BIOLOGICS SEGMENTATION
26.2.3 APAC: BIOLOGICS SEGMENTATION
26.2.4 LATIN AMERICA: BIOLOGICS SEGMENTATION
26.2.5 MIDDLE EAST & AFRICA: BIOLOGICS SEGMENTATION
26.3 SCALE OF OPERATION
26.3.1 NORTH AMERICA: SCALE OF OPERATION SEGMENTATION
26.3.2 EUROPE: SCALE OF OPERATION SEGMENTATION
26.3.3 APAC: SCALE OF OPERATION SEGMENTATION
26.3.4 LATIN AMERICA: SCALE OF OPERATION SEGMENTATION
26.3.5 MIDDLE EAST & AFRICA: SCALE OF OPERATION SEGMENTATION
26.4 END-USER
26.4.1 NORTH AMERICA: END-USER SEGMENTATION
26.4.2 EUROPE: END-USER SEGMENTATION
26.4.3 APAC: END-USER SEGMENTATION
26.4.4 LATIN AMERICA: END-USER SEGMENTATION
26.4.5 MIDDLE EAST & AFRICA: END-USER SEGMENTATION
26.5 GEOGRAPHY
26.5.1 BULKING AGENTS: GEOGRAPHY SEGMENTATION
26.5.2 SOLUBILIZERS & SURFACTANTS: GEOGRAPHY SEGMENTATION
26.5.3 BUFFERING & TONICITY AGENTS: GEOGRAPHY SEGMENTATION
26.5.4 OTHER EXCIPIENTS: GEOGRAPHY SEGMENTATION
26.5.5 MONOCLONAL ANTIBODIES: GEOGRAPHY SEGMENTATION
26.5.6 VACCINES: GEOGRAPHY SEGMENTATION
26.5.7 OTHER BIOLOGICS: GEOGRAPHY SEGMENTATION
26.5.8 COMMERCIAL: GEOGRAPHY SEGMENTATION
26.5.9 RESEARCH: GEOGRAPHY SEGMENTATION
26.5.10 PHARMA & BIOTECH COMPANIES: GEOGRAPHY SEGMENTATION
26.5.11 CMOS & CDMOS: GEOGRAPHY SEGMENTATION
26.5.12 ACADEMIC & RESEARCH INSTITUTES: GEOGRAPHY SEGMENTATION
27 APPENDIX
27.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
EXHIBIT 3 BIOPHARMACEUTICAL CLASSIFICATION SYSTEM OF EXCIPIENTS
EXHIBIT 4 LIST OF EXCIPIENTS INCLUDED IN EACH BCSE CLASS
EXHIBIT 5 SEGMENTATION OF GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 6 IMPACT OF EMERGING DEMAND FOR NOVEL EXCIPIENTS IN DRUG PRODUCT DEVELOPMENT
EXHIBIT 7 US FDA SOUGHT INDUSTRY INPUT ON NOVEL EXCIPIENTS
EXHIBIT 8 IMPACT OF HIGH DEMAND FOR VACCINES AND CELL & GENE THERAPY-BASED EXCIPIENTS
EXHIBIT 9 IMPACT OF EXHAUSTIVE PIPELINE OF BIOLOGICS & BIOSIMILARS
EXHIBIT 10 VACCINES IN PIPELINE FOR VARIOUS INFECTIOUS DISEASES
EXHIBIT 11 DCVMN PIPELINE: NUMBER OF VACCINE DEVELOPMENT PROJECTS (2019)
EXHIBIT 12 BIOSIMILARS IN DEVELOPMENT PHASES (2013 & 2020)
EXHIBIT 13 IMPACT OF GROWING PENETRATION OF BIOPHARMACEUTICAL DRUGS
EXHIBIT 14 AGGREGATE VALUE OF GLOBAL PHARMACEUTICAL INDUSTRY 2015–2020 ($ TRILLION)
EXHIBIT 15 IMPACT OF GROWING PREVALENCE OF CANCER & INFECTIOUS DISEASES
EXHIBIT 16 ESTIMATED NEW CASES OF TOP CANCERS IN 2022 (%)
EXHIBIT 17 REGIONAL PREVALENCE OF LEADING INFECTIOUS DISEASES
EXHIBIT 18 IMPACT OF RISING NUMBER OF PRODUCT APPROVALS FOR BIOLOGICS
EXHIBIT 19 US FDA APPROVALS OF NMES AND BIOLOGICS (2011-2020)
EXHIBIT 20 DEVELOPMENT OF BIOLOGIC MEDICINES BY PRODUCT CATEGORY
EXHIBIT 21 IMPACT OF INCREASING NEED FOR OUTSOURCING BIOPHARMACEUTICAL EXCIPIENT MANUFACTURING
EXHIBIT 22 IMPACT OF EMERGING NEED FOR MULTI-FUNCTIONAL EXCIPIENTS
EXHIBIT 23 IMPACT OF REGULATORY CHALLENGES IN MANUFACTURING BIOPHARMACEUTICAL EXCIPIENTS
EXHIBIT 24 IMPACT OF SUPPLY CHAIN AND INTEGRITY ISSUES WITH BIOPHARMACEUTICAL EXCIPIENTS
EXHIBIT 25 IMPACT OF CHALLENGES OF FORMULATING BIOPHARMACEUTICAL EXCIPIENTS
EXHIBIT 26 SEARCH RESULTS OF MOST COMMONLY OCCURRING EXCIPIENTS
EXHIBIT 27 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 28 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY TYPE
EXHIBIT 29 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS
EXHIBIT 30 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION
EXHIBIT 31 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER
EXHIBIT 32 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY
EXHIBIT 33 FIVE FORCES ANALYSIS 2021
EXHIBIT 34 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 35 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT
EXHIBIT 36 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT: INCREMENTAL GROWTH
EXHIBIT 37 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT: ABSOLUTE GROWTH
EXHIBIT 38 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BULKING AGENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 39 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BULKING AGENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 40 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 41 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS SOLUBILIZERS & SURFACTANTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 42 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS SOLUBILIZERS & SURFACTANTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 44 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BUFFERING & TONICITY AGENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 45 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS BUFFERING & TONICITY AGENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 46 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 47 GLOBAL OTHER BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 48 GLOBAL OTHER BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 49 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 50 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 51 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS
EXHIBIT 52 DISTRIBUTION OF INACTIVE INGREDIENTS IN BIOLOGIC FORMULATIONS
EXHIBIT 53 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS: INCREMENTAL GROWTH
EXHIBIT 54 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS: ABSOLUTE GROWTH
EXHIBIT 55 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 58 GLOBAL VACCINE EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 59 GLOBAL VACCINE EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 60 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 61 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS OTHER BIOLOGICS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 62 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY OTHER BIOLOGICS 2021–2027 ($ MILLION)
EXHIBIT 63 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 64 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 65 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION
EXHIBIT 66 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION: INCREMENTAL GROWTH
EXHIBIT 67 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION: ABSOLUTE GROWTH
EXHIBIT 68 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 69 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 70 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 71 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 72 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 73 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 74 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 75 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER
EXHIBIT 76 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER: INCREMENTAL GROWTH
EXHIBIT 77 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 78 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET 2021–2027 ($ MILLION)
EXHIBIT 80 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 81 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 82 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET 2021–2027 ($ MILLION)
EXHIBIT 83 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 84 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 85 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET 2021–2027 ($ MILLION)
EXHIBIT 86 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 87 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
EXHIBIT 88 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY
EXHIBIT 89 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: KEY COUNTRIES 2021 ($ MILLION)
EXHIBIT 90 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 91 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 92 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 93 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 94 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 95 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 96 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 97 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 98 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 99 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
EXHIBIT 100 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN US 2021–2027 ($ MILLION)
EXHIBIT 101 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN CANADA 2021–2027 ($ MILLION)
EXHIBIT 102 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 103 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 104 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 105 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 106 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 107 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 108 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 109 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
EXHIBIT 110 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN GERMANY 2021–2027 ($ MILLION)
EXHIBIT 111 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN FRANCE 2021–2027 ($ MILLION)
EXHIBIT 112 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN THE UK 2021–2027 ($ MILLION)
EXHIBIT 113 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SWITZERLAND 2021–2027 ($ MILLION)
EXHIBIT 114 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN ITALY 2021–2027 ($ MILLION)
EXHIBIT 115 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SPAIN 2021–2027 ($ MILLION)
EXHIBIT 116 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 117 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 118 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 119 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 120 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 121 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 122 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 123 INCREMENTAL GROWTH IN APAC 2021 & 2027
EXHIBIT 124 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN CHINA 2021–2027 ($ MILLION)
EXHIBIT 125 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN JAPAN 2021–2027 ($ MILLION)
EXHIBIT 126 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SOUTH KOREA 2021–2027 ($ MILLION)
EXHIBIT 127 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN INDIA 2021–2027 ($ MILLION)
EXHIBIT 128 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN AUSTRALIA 2021–2027 ($ MILLION)
EXHIBIT 129 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 130 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 131 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 132 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 133 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 134 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 135 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 136 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
EXHIBIT 137 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN BRAZIL 2021–2027 ($ MILLION)
EXHIBIT 138 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN MEXICO 2021–2027 ($ MILLION)
EXHIBIT 139 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN ARGENTINA 2021–2027 ($ MILLION)
EXHIBIT 140 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY COUNTRIES (2021)
EXHIBIT 141 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET: INCREMENTAL & ABSOLUTE GROWTH
EXHIBIT 142 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET 2021–2027 ($ MILLION)
EXHIBIT 143 INCREMENTAL GROWTH BY EXCIPIENT 2021 & 2027
EXHIBIT 144 INCREMENTAL GROWTH BY BIOLOGICS 2021 & 2027
EXHIBIT 145 INCREMENTAL GROWTH BY SCALE OF OPERATION 2021 & 2027
EXHIBIT 146 INCREMENTAL GROWTH BY END-USER 2021 & 2027
EXHIBIT 147 INCREMENTAL GROWTH IN THE MIDDLE EAST & AFRICA 2021 & 2027
EXHIBIT 148 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN TURKEY 2021–2027 ($ MILLION)
EXHIBIT 149 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SAUDI ARABIA 2021–2027 ($ MILLION)
EXHIBIT 150 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN THE UAE 2021–2027 ($ MILLION)
EXHIBIT 151 BIOPHARMACEUTICAL EXCIPIENTS MARKET IN SOUTH AFRICA 2021–2027 ($ MILLION)
EXHIBIT 152 PURE AND DIVERSIFIED PLAYERS IN THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 153 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET: KEY VENDOR STRENGTHS & CAPABILITY ANALYSIS
EXHIBIT 154 POSITION OF MAJOR PLAYERS IN THE GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET
EXHIBIT 155 MERCK KGAA: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 156 MERCK KGAA: REVENUE BY SEGMENT 2019–2021 ($ MILLION)
EXHIBIT 157 MERCK KGAA: TOTAL R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 158 MERCK KGAA: REVENUE BY GEOGRAPHY 2019–2021 ($ MILLION)
EXHIBIT 159 BASF: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 160 BASF: REVENUE BY SEGMENT 2019–2021 ($ MILLION)
EXHIBIT 161 BASF: TOTAL R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 162 BASF: REVENUE BY GEOGRAPHY 2019–2021 ($ MILLION)
EXHIBIT 163 AVANTOR: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 164 AVANTOR: REVENUE BY SEGMENT 2019–2021 ($ MILLION)
EXHIBIT 165 AVANTOR: REVENUE BY PRODUCT LINE 2019–2021 ($ MILLION)
EXHIBIT 166 EVONIK INDUSTRIES: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 167 EVONIK INDUSTRIES: REVENUE BY SEGMENT 2020–2021 ($ MILLION)
EXHIBIT 168 EVONIK INDUSTRIES: TOTAL R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 169 EVONIK INDUSTRIES: REVENUE BY GEOGRAPHY 2019–2021 ($ MILLION)
EXHIBIT 170 ASSOCIATED BRITISH FOODS: TOTAL REVENUE 2019–2021 ($ MILLION)
EXHIBIT 171 ASSOCIATED BRITISH FOODS: REVENUE BY SEGMENT 2019–2021 ($ MILLION)
EXHIBIT 172 ASSOCIATED BRITISH FOODS: TOTAL R&D EXPENDITURE 2019–2021 ($ MILLION)
EXHIBIT 173 ASSOCIATED BRITISH FOODS: REVENUE BY GEOGRAPHY 2019–2021 ($ MILLION)
EXHIBIT 174 MEGGLE: MAJOR PRODUCT OFFERINGS
EXHIBIT 175 PFANSTIEHL: MAJOR PRODUCT OFFERINGS
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2021
TABLE 3 EXCIPIENTS USED IN BIOPHARMACEUTICAL FORMULATIONS & THEIR EFFECTS
TABLE 4 CATEGORIES AND EXAMPLES OF SOME BIOPHARMACEUTICAL EXCIPIENTS IN FORMULATING VACCINES
TABLE 5 EXAMPLES OF EXCIPIENTS IN US LICENSED CELL & GENE THERAPY PRODUCTS
TABLE 6 PERCENTAGE SHARE OF VARIOUS BIOPHARMACEUTICALS WITH SMALL MOLECULES 2015 & 2020
TABLE 7 TOTAL REVENUE SHARE OF BIOPHARMACEUTICALS AMONG TOP PHARMACEUTICAL COMPANIES (2012)
TABLE 8 MERCK KGAA: MAJOR PRODUCT OFFERINGS
TABLE 9 BASF: MAJOR PRODUCT OFFERINGS
TABLE 10 AVANTOR: MAJOR PRODUCT OFFERINGS
TABLE 11 EVONIK INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 12 ROQUETTE FRÈRES: MAJOR PRODUCT OFFERINGS
TABLE 13 ASSOCIATED BRITISH FOODS: MAJOR PRODUCT OFFERINGS
TABLE 14 ACETO: MAJOR PRODUCT OFFERINGS
TABLE 15 ANGUS CHEMICAL COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 16 APOTHECON PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
TABLE 17 ASHLAND: MAJOR PRODUCT OFFERINGS
TABLE 18 BIOSPECTRA: MAJOR PRODUCT OFFERINGS
TABLE 19 BOC SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 20 CG GROUP: MAJOR PRODUCT OFFERINGS
TABLE 21 CLARIANT: MAJOR PRODUCT OFFERINGS
TABLE 22 COLORCON: MAJOR PRODUCT OFFERINGS
TABLE 23 DFE PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 24 DOW: MAJOR PRODUCT OFFERINGS
TABLE 25 EASTMAN CHEMICAL COMPANY: MAJOR PRODUCT OFFERINGS
TABLE 26 IMCD: MAJOR PRODUCT OFFERINGS
TABLE 27 INNOPHOS: MAJOR PRODUCT OFFERINGS
TABLE 28 INVITRIA: MAJOR PRODUCT OFFERINGS
TABLE 29 JRS PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 30 KIRSCH PHARMA: MAJOR PRODUCT OFFERINGS
TABLE 31 NOVO NORDISK: MAJOR PRODUCT OFFERINGS
TABLE 32 PHARMONIX BIOLOGICALS: MAJOR PRODUCT OFFERINGS
TABLE 33 SHIN-ETSU CHEMICAL: MAJOR PRODUCT OFFERINGS
TABLE 34 SIGACHI INDUSTRIES: MAJOR PRODUCT OFFERINGS
TABLE 35 SPECTRUM CHEMICAL: MAJOR PRODUCT OFFERINGS
TABLE 36 TEREOS: MAJOR PRODUCT OFFERINGS
TABLE 37 THE LUBRIZOL CORPORATION: MAJOR PRODUCT OFFERINGS
TABLE 38 WACKER CHEMIE: MAJOR PRODUCT OFFERINGS
TABLE 39 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 ($ MILLION)
TABLE 40 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 (%)
TABLE 41 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 ($ MILLION)
TABLE 42 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 (%)
TABLE 43 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 ($ MILLION)
TABLE 44 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 (%)
TABLE 45 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 ($ MILLION)
TABLE 46 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 (%)
TABLE 47 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 ($ MILLION)
TABLE 48 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 (%)
TABLE 49 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 ($ MILLION)
TABLE 50 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT 2021−2027 (%)
TABLE 51 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 ($ MILLION)
TABLE 52 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 53 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 ($ MILLION)
TABLE 54 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 55 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 ($ MILLION)
TABLE 56 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 57 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 ($ MILLION)
TABLE 58 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 59 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 ($ MILLION)
TABLE 60 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 61 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 ($ MILLION)
TABLE 62 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY BIOLOGICS 2021−2027 (%)
TABLE 63 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 ($ MILLION)
TABLE 64 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 65 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 ($ MILLION)
TABLE 66 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 67 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 ($ MILLION)
TABLE 68 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 69 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 ($ MILLION)
TABLE 70 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 71 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 ($ MILLION)
TABLE 72 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 73 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 ($ MILLION)
TABLE 74 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY SCALE OF OPERATION 2021−2027 (%)
TABLE 75 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 76 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 (%)
TABLE 77 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 78 NORTH AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 (%)
TABLE 79 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 80 EUROPE BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 (%)
TABLE 81 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 82 APAC BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 (%)
TABLE 83 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 84 LATIN AMERICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 (%)
TABLE 85 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 ($ MILLION)
TABLE 86 MIDDLE EAST & AFRICA BIOPHARMACEUTICAL EXCIPIENTS MARKET BY END-USER 2021−2027 (%)
TABLE 87 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 88 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 89 GLOBAL BIOPHARMACEUTICAL BULKING AGENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 90 GLOBAL BIOPHARMACEUTICAL BULKING AGENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 91 GLOBAL BIOPHARMACEUTICAL SOLUBILIZERS & SURFACTANTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 92 GLOBAL BIOPHARMACEUTICAL SOLUBILIZERS & SURFACTANTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 93 GLOBAL BIOPHARMACEUTICAL BUFFERING & TONICITY AGENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 94 GLOBAL BIOPHARMACEUTICAL BUFFERING & TONICITY AGENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 95 GLOBAL BIOPHARMACEUTICAL OTHER EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 96 GLOBAL BIOPHARMACEUTICAL OTHER EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 97 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 98 GLOBAL MONOCLONAL ANTIBODY EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 99 GLOBAL VACCINE EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 100 GLOBAL VACCINE EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 101 GLOBAL OTHER BIOLOGICS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 102 GLOBAL OTHER BIOLOGICS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 103 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 104 GLOBAL COMMERCIAL BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 105 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 106 GLOBAL RESEARCH BIOPHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 107 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 108 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS PHARMA & BIOTECH COMPANIES MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 109 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 110 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS CMOS & CDMOS MARKET BY GEOGRAPHY 2021−2027 (%)
TABLE 111 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2021−2027 ($ MILLION)
TABLE 112 GLOBAL BIOPHARMACEUTICAL EXCIPIENTS ACADEMIC & RESEARCH INSTITUTES MARKET BY GEOGRAPHY 2021−2027 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
